Search trials – HealthDB

AI · cancer

Намерени 1,748 изпитвания за "cancer" Стр. 83 от 88

Active (not recruiting)

Supportive Oncology Care At Home RCT

Pancreatic Cancer GastroEsophageal Cancer Rectal Cancer Head and Neck Cancer +1

This research study is evaluating a program that entails remote monitoring and home-based care for people with cancer who are receiving chemotherapy, radiotherapy, or chemoradiotherapy.

Начало: 16.09.2020 Край: 31.12.2026 Възраст: от 18 г.

United States Massachusetts General Hospital NCT04544046

Active (not recruiting) Phase 3

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Myelofibrosis (MF)

Myelofibrosis (MF) is a rare blood cancer, notable for scarring of the bone marrow (the spongy tissue inside bones) and the spleen becoming larger. The purpose of this study is to assess safety and change in spleen volume when navitoclax is given in combination with ruxolitinib, compared to best available therapy, for adult participants with MF. Navitoclax is an investigational drug (not yet approved) being developed for the treatment of MF. Participants in this study will be randomly selected (like picking numbers out of a hat) to be in 1 of 2 treatment arms. Neither participants nor the study doctor will be able to pick which treatment arm a participants enters. In Arm A, participants will receive navitoclax in combination with ruxolitinib. In Arm B, participants will receive the best available therapy (BAT) for MF. In Arm C, participants will receive navitoclax. Adult participants with a diagnosis of MF that came back or did not get better after earlier treatment will be enrolled. Approximately 330 participants will be enrolled in approximately 322 sites across the world. In Arm A, participants will receive navitoclax tablet by mouth once daily with by mouth ruxolitinib tablet twice daily. In Arm B, participants will receive the BAT available to the investigator. In Arm C, participants will receive navitoclax tablet by mouth once daily. Participants will receive the study drug until they experience no benefit (determined by the investigator), participants cannot tolerate the study drugs, or participants withdraw consent. The approximate treatment duration is about 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of treatment will be checked by medical assessments, blood and bone marrow tests, checking for side effects, and completing questionnaires.

Начало: 31.08.2020 Край: 01.12.2026 Възраст: от 18 г. Treatment

Australia, Belgium, Bulgaria +24 AbbVie NCT04468984

Active (not recruiting) Phase 3

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma

Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment. The trial will study whether brentuximab vedotin plus two drugs works better to treat this type of cancer than the two drugs alone. Participants will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is "blinded," participants and their doctors will not know whether a participant gets brentuximab vedotin or placebo. All participants in the study will get rituximab and lenalidomide. These are drugs that can be used to treat DLBCL.

Начало: 20.08.2020 Край: 31.12.2026 Възраст: от 18 г. Treatment

Australia, Belgium, Canada +11 Seagen, a wholly owned subsidiary of Pfizer NCT04404283

Active (not recruiting) Phase 1/2

Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy

Prostatic Neoplasms

This clinical trial will evaluate the dosimetry, efficacy and toxicity of Lu-PSMA in men with high PSMA-expressing high-risk localized or locoregional advanced prostate cancer (HRCaP) undergoing radical prostatectomy (RP) and pelvic lymph node dissection (PLND)

Начало: 06.08.2020 Край: 30.08.2025 Възраст: от 18 г. Treatment

Australia Peter MacCallum Cancer Centre, Australia NCT04430192

Active (not recruiting) Phase 2

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Ependymoma Recurrent Ewing Sarcoma Recurrent Hepatoblastoma Recurrent Langerhans Cell Histiocytosis +29

This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors, including central nervous system tumors, lymphomas and histiocytic disorders that have not responded to (refractory) or have come back after (recurrent) prior treatment that have IDH (isocitrate dehydrogenase) 1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the IDH pathway.

Начало: 20.07.2020 Край: 09.05.2026 Възраст: 12–21 г. Treatment

Australia, Puerto Rico, United States National Cancer Institute (NCI) NCT04195555

Active (not recruiting) Phase 3

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Relapsed/Refractory Follicular Lymphoma Follicular Lymphoma Refractory Follicular Lymphoma

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.

Начало: 11.06.2020 Край: 01.03.2029 Възраст: от 18 г. Treatment

Australia, Belgium, Brazil +14 Epizyme, Inc. NCT04224493

Active (not recruiting) Phase 1

Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM

Glioblastoma Multiforme

This phase I trial studies the side effects of stereotactic radiosurgery with MBG453 and spartalizumab in treating patients with recurrent glioblastoma multiforme (GBM). Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor to more precisely target the cancer. Monoclonal antibodies, such as MBG453 and spartalizumab may interfere with the ability of tumor cells to grow and spread. Giving stereotactic radiosurgery together with immunotherapy may be a better treatment for GBM.

Начало: 18.02.2020 Край: 01.09.2026 Възраст: от 18 г.

United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopk NCT03961971

Active (not recruiting) Phase 3

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations

Начало: 13.02.2020 Край: 01.06.2026 Възраст: от 18 г. Treatment

Australia, Greece, Hungary +10 Yuhan Corporation NCT04248829

Active (not recruiting) Phase 1/2

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

Desmoplastic Small Round Cell Tumor

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.

Начало: 22.01.2020 Край: 01.10.2026 Възраст: 12–29 г. Treatment

Australia, Germany, Italy +4 Eli Lilly and Company NCT04145349

Active (not recruiting)

Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)

Liver Cancer

Primary and secondary liver cancer patients will receive liver SABR with or without KIM intervention.

Начало: 14.01.2020 Край: 01.01.2026 Възраст: 18–85 г. Treatment

Australia University of Sydney NCT02984566

Active (not recruiting) Phase 2

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

The aim of this study is to potentiate adaptive immunity to enhance the anti-tumor activity of anti-PD1 antibody by the addition of anti-CTLA4 antibody or anti-LAG3 antibody (relatlimab) given in subjects with resectable locally advanced HNSCC prior to surgical resection.

Начало: 20.12.2019 Край: 17.10.2026 Възраст: от 18 г.

United States Dan Zandberg NCT04080804

Active (not recruiting) Phase 3

Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease

Metastatic Malignant Neoplasm in the Brain

This phase III trial studies how well single fraction stereotactic radiosurgery works compared with fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. This study may help doctors find out if fractionated stereotactic radiosurgery is better or worse than the usual approach with single fraction stereotactic radiosurgery.

Начало: 19.11.2019 Край: 01.09.2028 Възраст: от 18 г.

Canada, United States Alliance for Clinical Trials in Oncology NCT04114981

Active (not recruiting) Phase 2

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Solid Tumors

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

Начало: 18.11.2019 Край: 29.06.2026 Възраст: от 18 г. Treatment

Argentina, Australia, Canada +20 Merck Sharp & Dohme LLC NCT04123366

Active (not recruiting)

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer

Metastatic Tumors

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques. SABR is non-invasive and delivered on an outpatient basis. The purpose of this study is to compare the effect of SABR, relative to standard of care (SOC) alone, on overall survival, progression-free survival, toxicity, and quality of life. An integrated economic evaluation will determine the cost per quality of life year gained using SABR (vs. SOC) and a translational component will enable identification of predictive/prognostic biomarkers of the oligometastatic state.

Начало: 01.11.2019 Край: 31.12.2030 Възраст: от 18 г. Treatment

Australia, Canada, Ireland +1 British Columbia Cancer Agency NCT03862911

Active (not recruiting) Phase 2

Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors

Metastatic Solid Tumor

The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.

Начало: 15.10.2019 Край: 01.12.2026 Възраст: от 18 г. Treatment

Australia, Belgium, Canada +5 Gilead Sciences NCT03964727

Active (not recruiting) Phase 2

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Cutaneous Squamous Cell Carcinoma Advanced Cutaneous Squamous Cell Carcinoma Metastatic Cutaneous Squamous Cell Carcinoma

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.

Начало: 08.10.2019 Край: 01.09.2025 Възраст: от 18 г. Treatment

Australia, Bulgaria, Canada +7 Replimune, Inc. NCT04050436

Active (not recruiting) Phase 1/2

COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC

Metastatic Microsatellite-stable Colorectal Cancer

COLUMBIA-1 is a Phase 1b/2 platform study to evaluate the safety and efficacy of standard of care (FOLFOX plus bevacizumab) alone and in combination with novel oncology therapies in first-line metastatic microsatellite-stable colorectal cancer (MSS-CRC).

Начало: 13.09.2019 Край: 24.11.2026 Възраст: 18–101 г. Treatment

Australia, Canada, France +2 MedImmune LLC NCT04068610

Active (not recruiting) Phase 2

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer EGFR Gene Mutation Advanced Cancer Metastatic Cancer

The primary objective of the study is to evaluate the efficacy of osimertinib plus ramucirumab versus osimertinib alone using progression free survival (PFS). Events associated with PFS include: disease progression per RECIST 1.1 and death due to any cause. A total of 150 patients will be enrolled and randomized in a 2:1 fashion (osimertinib plus ramucirumab vs. osimertinib) to the two treatment arms according to the following stratification factors: types of epidermal growth factor receptor (EGFR) mutations and presence of brain metastasis.

Начало: 25.07.2019 Край: 01.01.2027 Възраст: от 18 г.

United States Xiuning Le NCT03909334

Active (not recruiting) Phase 2

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Melanoma

The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.

Начало: 18.07.2019 Край: 30.11.2032 Възраст: от 18 г. Treatment

Australia, United States ModernaTX, Inc. NCT03897881

Active (not recruiting)

A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer

Gynecologic Cancer Cervical Cancer

This research is studying the level of oxygen in tumors during the brachytherapy procedure.

Начало: 16.07.2019 Край: 15.12.2026 Възраст: от 18 г.

United States Brigham and Women's Hospital NCT03970083

1 … 81 82 83 84 85 … 88